LISINOPRIL
Lisinopril is an ACE inhibitor that lowers blood pressure by reducing angiotensin II production and decreasing aldosterone secretion. Benefits include improved cardiac function and kidney protection. Side effects include cough, dizziness, hyperkalemia, and rare angioedema.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
LISINOPRIL (ID 26566) demonstrates a high‑complexity biochemical profile involving modulation of receptor systems, enzyme‑regulated metabolic pathways, mitochondrial performance, intracellular ion dynamics and transcription‑level regulation. Its structural properties support binding to catalytic and regulatory protein domains, altering phosphorylation cascades, redox‑state equilibrium, cellular stress‑response thresholds and mitochondrial signalling output.
The molecule may influence calcium flux, ATP turnover, ROS–antioxidant balance, cytoskeletal organisation and membrane‑potential stability depending on the biological system and concentration applied.
Benefits and Advantages
Widely applied in mechanistic and pharmacodynamic research, including:
- Receptor‑ligand interaction analysis and affinity profiling
- Enzyme‑kinetic and catalytic‑pathway investigations
- Mitochondrial‑function, metabolic‑flux and oxidative‑stress studies
- Multi‑omics research: transcriptomics, proteomics and metabolomics
- Cell‑stress signalling, apoptosis/autophagy modelling and cytoskeletal‑dynamics mapping
- Preclinical screening, SAR modelling and comparative mechanistic benchmarking
Side Effects and Risks
Potential risks include oxidative imbalance, mitochondrial strain, unintended receptor cross‑activation, ion‑channel perturbation, metabolic rewiring, and dose‑dependent cytotoxicity. High exposure may induce apoptosis, autophagy, inflammatory signalling or transcriptional destabilisation. Strict laboratory safety protocols and controlled handling conditions are required.
Datasheet
| Molecular Formula | C21H31N3O5 |
|---|---|
| Molecular Weight | 405.5 g/mol |
| CAS Number | 76547-98-3 |
| Storage Condition | Keep container tightly closed in a dry and well-ventilated place. Storage class (TRGS 510): Non Combustible Solids. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | lisinopril; 76547-98-3; Prinivil; Zestril; Lisinopril anhydrous |
| IUPAC/Chemical Name | (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid |
| InChl Key | RLAWWYSOJDYHDC-BZSNNMDCSA-N |
| InChl Code | InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

